fda and semaglutide Clears For Cardiac Risk Reduction in Diabetic Patients FDA Approves Semaglutide for MASH

While previous generations of peptides focused on one or two receptors to manage appetite and insulin, Retatrutide introduces a third mechanismGlucagon Receptor Agonismwhich actively increases energy expenditure

Costa, L

doi: 10.3389/fcvm.2021.723886 Received 11 June 2021 Accepted 14 October 2021 Published 23 November 2021 Volume 8 - 2021 Edited by Dianjianyi Sun, Peking University, China Reviewed by Nhat Tu Le, Houston Methodist Research Institute, United States

Forbes SC, Cordingley DM, Cornish SM, Gualano B, Roschel H, Ostojic SM, et al

In the STEP 1 trial , 1,961 adults with a BMI of 30 or higher (or 27 with weight-related health conditions) took weekly doses of Semaglutide 2.4 mg for 68 weeks